Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469077 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9469286 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9469673 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9468782 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9468961 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9469386 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9468929 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9468950 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9468818 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL9469806 | 1.00 | MEN1 (1.00) | MEN1KMT2ATP53CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238019-A1 | STEM CELL CULTURE MEDIA FOR MAINTAINING STEMNESS OR INDUCING DIFFERENTIATION OF STEM CELLS | COLLEGE OF MEDICINE POCHON CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-09-20 | — | — | US | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-5189046-A | Antiinflammatory agents, anticonvulsants | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-02-23 | — | — | US | claimed |
| WO-1992003415-A1 | PROTEIN KINASE C MODULATORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-03-05 | — | — | WO | claimed |
| US-20250032530-A1 | USE OF AURANOFIN AS AN INHIBITOR OF ATYPICAL PROTEIN KINASE C FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | UNIVERSITY OF SOUTH FLORIDA | 2025-01-30 | — | — | US | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2024-11-28 | — | — | US | disclosed |
| EP-4440313-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | Institut national de recherche pour l'agriculture, L'alimentation et l'environnement (INRAE) (FR) | 2024-10-09 | — | — | EP | disclosed |
| CN-118714927-A | Compositions and methods for controlling phytopathogenic infection | 法国国家农业食品与环境研究院 | 2024-09-27 | — | — | CN | disclosed |
| US-20230288429-A1 | REAL TIME ELECTRONIC CELL SENSING SYSTEMS AND APPLICATIONS FOR CELL-BASED ASSAYS | AGILENT TECHNOLOGIES, INC. | 2023-09-14 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023099609-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2023-06-08 | — | — | WO | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| EP-1503735-A2 | A DIRECT CELLULAR ENERGY DELIVERY SYSTEM | University of Louisville Research Foundation, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003096973-A2 | A DIRECT CELLULAR ENERGY DELIVERY SYSTEM | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5189046-A | Antiinflammatory agents, anticonvulsants | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-02-23 | — | — | US | disclosed |
| WO-1992003415-A1 | PROTEIN KINASE C MODULATORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | MEN1 419/4885KMT2A 3596/4885TP53 1584/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | MEN1 4876/4885KMT2A 1830/4885TP53 1236/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | MEN1 4870/4885KMT2A 1426/4885TP53 1288/4885 |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | XBP1, ERN1, ERN2 | MEN1 3635/4885KMT2A 4467/4885TP53 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.